MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma

Figures & data

Figure 1. The workflow of the present study.

Table 1. Summary of patient cohort information.

Characteristic	Training set		Test set		P
	Numbers	%	Numbers	%
Sex
Male	125	46.82%	82	46.33%	0.919
Female	142	53.18%	95	53.67%
Age
<65 year	122	45.69%	74	41.81%	0.426
≥65 year	136	50.94%	93	52.54%
Not available	9	3.37%	10	5.65%
T
T1-2	236	88.39%	149	84.18%	0.432
T3-4	30	11.24%	26	14.69%
Tx	1	0.37%	2	1.13%
N
N0	177	66.29%	113	63.84%	0.064
N1-3	88	32.96%	57	32.20%
Nx/Not available	2	0.75%	7	3.95%
M
M0	165	61.80%	118	66.67%	0.359
M1	14	5.24%	5	2.82%
Mx/Not available	88	32.96%	54	30.51%
Stage
I-II	211	79.03%	137	77.40%	0.182
III-IV	55	20.60%	36	20.34%
Not available	1	0.37%	4	2.26%

Figure 2. Hierarchical clustering dendrograms of the expression patterns of differently expressed microRNAs that can basically distinguish between high TMB and low TMB in lung adenocarcinoma.

Figure 3. LASSO model and principal component analysis. (a) 10‑fold cross‑validation for tuning parameter selection in the LASSO model. (b) PCA prior to and (c) after LASSO variable reduction. LASSO, least absolute shrinkage and selection operator; PCA, principal component analysis.

Table 2. Performance of 25-miRNA-based classifiers of tumor mutation burden in lung adenocarcinoma.

Cohort	Se	Sp	PPV	NPV	Accuracy	AUC
Training set	0.770	0.960	0.500	0.960	0.850	0.895
Test set	0.670	0.960	0.260	0.960	0.810	0.826
Total set	0.740	0.960	0.400	0.960	0.840	0.867

AUC, area under the receiver operating characteristic curve; NPV, negative predictive value; PPV, positive predictive value; Se, sensitivity; Sp, specificity.

Figure 4. Receiver operating characteristic curves for the 25-miRNA-based signature index and its correlation with TMB, PD-1, PD-L1 and CTLA-4. (a) Receiver operating characteristic analyses in the training and the test set. (b) Receiver operating characteristic analyses in the total set. (c) The 25-miRNA-based signature index is highly correlated with TMB (d) The 25-miRNA-based signature index shows low correlation with PD-1 expression. (e) The 25-miRNA-based signature index shows low correlation with PD-L1 expression. (f) The 25-miRNA-based signature index is not correlated with CTLA4 expression.

Figure 5. Enrichment analysis of the 25 miRNAs. (a) Significantly enriched immune-related biological process GO terms and (b) Significantly enriched cancer-related KEGG pathways.